Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today shared data showcasing the clinical benefits of camonsertib, a promising oral small molecule ATR inhibitor, used in combination with palliative radiation for treating metastatic tumors with an ataxia-telangiectasia-mutated (ATM) mutation.
Data from a clinical trial conducted in collaboration with Memorial Sloan Kettering Cancer Center were presented at the American Society for Radiation Oncology (ASTRO) annual meeting in Washington, DC, by Dr. Nancy Lee, Radiation Oncologist and Early Drug Development Specialist. The presentation was titled “Genotypically-Selected Pan Cancer Trial of Camonsertib with Palliative Radiation in the Treatment of Metastatic Tumors Harboring an Ataxia-Telangiectasia Mutated (ATM) Mutation.”
“These encouraging early Phase 1 data further support the broad clinical potential of camonsertib,” said Dr. Maria Koehler, Executive Vice President and Chief Medical Officer of Repare. “This first-in-human study combining camonsertib, an ATR inhibitor, with palliative radiation shows early clinical data indicating that this combination could enhance radiosensitivity for greater clinical benefit in patients with tumors harboring pathogenic ATM mutations, compared to those with variants of unknown significance. We are optimistic about the early response rate and safety profile of this combination in the Phase 1 setting.”
Key Study Findings:
- Seventeen patients with metastatic tumors harboring ATM mutations were enrolled, including 12 with pathogenic mutations and 5 with variants of unknown significance (VUS).
- Primary cancer types included gastrointestinal (n=5), pancreas (n=5), breast (n=2), lung (n=2), bladder (n=2), and thyroid (n=1).
- The recommended Phase 2 dose for camonsertib was established as 160 mg taken once daily prior to radiation (4Gy) on days 1-5.
- Interim response data were available for 16 patients:
- At 2 months, the pathogenic ATM mutation group showed 2 complete responses (CR), 5 partial responses (PR), and 4 stable diseases (SD), while the VUS group had 1 PR and 4 SD.
- At 6 months, among 9 evaluable patients, the pathogenic group reported 2 CR, 4 PR, and 1 SD, compared to 1 SD and 1 progressive disease (PD) in the VUS group.
About Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company utilizing its proprietary synthetic lethality approach to develop novel therapeutics. The company employs its CRISPR-enabled SNIPRx® platform for systematic discovery and development of targeted cancer therapies focused on genomic instability and DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 development; camonsertib (RP-3500), a potential leading ATR inhibitor also in Phase 1/2; RP-1664, a Phase 1 PLK4 inhibitor; and RP-3467, a preclinical Polθ ATPase inhibitor, among additional undisclosed preclinical programs.
